Serving ACOs, IDNs & Emerging Provider Networks: Health Outcomes and Future Trends

Non-members: Click here to review a complimentary excerpt from "Serving ACOs, IDNs & Emerging Provider Networks: Health Outcomes and Future Trends"

STUDY OVERVIEW

As a result of the Affordable Care Act on the U.S. healthcare industry, Accountable Care Organizations (ACOs) and Integrated Delivery Networks (IDNs) are playing a bigger role in the payer sector and are accounting for a fast-rising share of total pharma business.

Best Practices, LLC conducted a customized study to better understand the current and expected impact of ACOs/IDNs on pharma companies’ operations. The research also reviews which health outcomes activities can influence ACO/IDN relationships and provides participants' lessons learned regarding the use of ACO/IDN specialists. The study provides Sales and Managed Markets leaders with benchmarks for current and future trends and lessons learned when serving ACOs/IDNs.

This study has small/medium company and large company segments.

KEY TOPICS

• Employing Health Outcomes
• Current and Future Trends
• Lessons Learned

SAMPLE KEY METRICS

• Top ways to partner with ACOs/IDNs to influence payers
• Types of outcomes research most valued by ACOs/IDNs
• Lessons learned for productively using ACO/IDN specialists

SAMPLE KEY FINDING

• Treatment protocols will be developed and standardized at the top level in ACO/IDN networks, and cascaded to practitioners within. This practice reduces physicians' treatment options and potentially prevents patient access to effective pharma products.

METHODOLOGY

This study engaged 36 leaders at 31 pharma and medical device companies through a benchmarking survey. Analysts also conducted in-depth executive interviews to develop qualitative findings and insights.

Industries Profiled:
Pharmaceutical; Medical Device; Biotech; Health Care; Chemical; Diagnostic


Companies Profiled:
Teva Pharmaceutical Industries Ltd; Biotronik; Pfizer; Dexcom; Medtronic; CooperSurgical; Genentech; CardioDX; AstraZeneca; Mist Pharmaceuticals; Amgen; GSMS; GlaxoSmithKline ; S3; Novo Nordisk; Astellas; Endo Pharmaceuticals; Mylan; B.Braun; MedImmune; Stryker Neurovascular; Auxilium; Galderma; Purdue Pharma; Centurion; Vivus; Orthofix; Greer Laboratories; Biocon; Myriad; Smith & Nephew

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.